Erenumab for Migraine

CTAF
June 22, 2018 10am - 4pm PT

CTAF will convene to review ICER's report on erenumab for prevention of migraine headaches. During this meeting, CTAF will also review a condition update on plaque psoriasis therapies.

Key Dates

Associated Materials

11/09/2017 – 11/30/2017

12/04/2017
Draft Scoping Document

12/04/2017
Stakeholder List

12/04/2017 – 12/22/2017
Public Comments

01/09/2018
Revised Scoping Document

04/19/2018
Draft Evidence Report

04/19/2018
Draft Voting Questions

04/19/2018 – 05/16/2018
Public Comments

06/08/2018
Evidence Report

06/08/2018
Revised Voting Questions

06/08/2018
Response to Comments

06/22/2018
Meeting Agenda

07/09/2018
Final Evidence Report and Meeting Summary